2021 Q1 Form 10-K Financial Statement

#000156459021016653 Filed on March 30, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2020
Revenue $1.658M $1.476M $7.128M
YoY Change -29.75% -47.97% -24.75%
Cost Of Revenue $615.0K $643.0K $2.781M
YoY Change -28.24% -55.22% -29.29%
Gross Profit $1.043M $833.0K $4.347M
YoY Change -30.61% -40.54% -21.52%
Gross Profit Margin 62.91% 56.44% 60.98%
Selling, General & Admin $1.395M $1.336M $6.177M
YoY Change -15.71% -61.83% -25.94%
% of Gross Profit 133.75% 160.38% 142.1%
Research & Development $215.0K $988.0K
YoY Change -29.04% -28.72%
% of Gross Profit 20.61% 22.73%
Depreciation & Amortization $66.00K $61.00K $253.0K
YoY Change 4.76% -25.61% -11.23%
% of Gross Profit 6.33% 7.32% 5.82%
Operating Expenses $1.395M $1.566M $7.165M
YoY Change 360.4% -59.69% -26.34%
Operating Profit -$567.0K -$733.0K -$2.818M
YoY Change 24.62% -70.49% -50.8%
Interest Expense $32.00K $12.00K $113.0K
YoY Change 14.29% -105.24% 46.75%
% of Operating Profit
Other Income/Expense, Net -$32.00K $94.00K
YoY Change -139.02% -93.57%
Pretax Income -$599.0K -$721.0K -$2.724M
YoY Change 60.59% -73.42% -36.13%
Income Tax
% Of Pretax Income
Net Earnings -$599.0K -$721.0K -$2.724M
YoY Change 60.59% -73.42% -36.13%
Net Earnings / Revenue -36.13% -48.85% -38.22%
Basic Earnings Per Share
Diluted Earnings Per Share -$79.45K -$95.64K -$361.3K
COMMON SHARES
Basic Shares Outstanding 7.539M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.117M $689.0K $689.0K
YoY Change 57.77% 42.36% 42.36%
Cash & Equivalents $1.117M $689.0K
Short-Term Investments
Other Short-Term Assets $437.0K $174.0K $174.0K
YoY Change 0.69% -15.94% -15.94%
Inventory $1.055M $917.0K $917.0K
Prepaid Expenses
Receivables $437.0K $403.0K $403.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $3.046M $2.183M $2.183M
YoY Change -9.88% -36.76% -36.76%
LONG-TERM ASSETS
Property, Plant & Equipment $1.297M $534.0K $1.408M
YoY Change 105.87% -20.06% 1.66%
Goodwill
YoY Change
Intangibles $1.262M
YoY Change -5.47%
Long-Term Investments
YoY Change
Other Assets $434.0K $434.0K $434.0K
YoY Change -3.13% -3.13% -3.13%
Total Long-Term Assets $2.973M $3.104M $3.104M
YoY Change -14.96% -2.02% -2.02%
TOTAL ASSETS
Total Short-Term Assets $3.046M $2.183M $2.183M
Total Long-Term Assets $2.973M $3.104M $3.104M
Total Assets $6.019M $5.287M $5.287M
YoY Change -12.46% -20.14% -20.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $512.0K $360.0K $360.0K
YoY Change -4.12% -44.95% -44.95%
Accrued Expenses $888.0K $386.0K $732.0K
YoY Change 23.68% -39.88% -27.45%
Deferred Revenue
YoY Change
Short-Term Debt $2.852M $0.00 $0.00
YoY Change 19.08%
Long-Term Debt Due $219.0K $141.0K $141.0K
YoY Change
Total Short-Term Liabilities $4.721M $1.483M $1.483M
YoY Change 12.27% -22.48% -22.48%
LONG-TERM LIABILITIES
Long-Term Debt $915.0K $2.992M $2.992M
YoY Change 26.24% 26.24%
Other Long-Term Liabilities $781.0K $845.0K $845.0K
YoY Change -35.67% -8.65% -8.65%
Total Long-Term Liabilities $1.696M $3.837M $3.837M
YoY Change 39.7% 16.45% 16.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.721M $1.483M $1.483M
Total Long-Term Liabilities $1.696M $3.837M $3.837M
Total Liabilities $6.417M $5.320M $5.320M
YoY Change 18.42% 2.15% 2.15%
SHAREHOLDERS EQUITY
Retained Earnings -$109.1M
YoY Change 2.56%
Common Stock $8.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.698M -$4.333M -$33.00K
YoY Change
Total Liabilities & Shareholders Equity $6.019M $5.287M $5.287M
YoY Change -12.46% -20.14% -20.14%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2020
OPERATING ACTIVITIES
Net Income -$599.0K -$721.0K -$2.724M
YoY Change 60.59% -73.42% -36.13%
Depreciation, Depletion And Amortization $66.00K $61.00K $253.0K
YoY Change 4.76% -25.61% -11.23%
Cash From Operating Activities -$394.0K -$311.0K -$341.0K
YoY Change -248.68% -18.37% -75.59%
INVESTING ACTIVITIES
Capital Expenditures -$2.000K -$26.00K $28.00K
YoY Change -166.67% -73.47% -82.93%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.000K -$26.00K -$108.0K
YoY Change -95.12% -73.47% -78.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 824.0K 0.000 654.0K
YoY Change -100.0% -49.69%
NET CHANGE
Cash From Operating Activities -394.0K -311.0K -341.0K
Cash From Investing Activities -2.000K -26.00K -108.0K
Cash From Financing Activities 824.0K 0.000 654.0K
Net Change In Cash 428.0K -337.0K 205.0K
YoY Change 91.07% -1704.76% -134.69%
FREE CASH FLOW
Cash From Operating Activities -$394.0K -$311.0K -$341.0K
Capital Expenditures -$2.000K -$26.00K $28.00K
Free Cash Flow -$392.0K -$285.0K -$369.0K
YoY Change -249.62% 0.71% -76.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 isco Paycheck Protection Program Loan Maturity Period
PaycheckProtectionProgramLoanMaturityPeriod
P2Y
CY2020Q2 isco Paycheck Protection Program Loan Forgiveness Period
PaycheckProtectionProgramLoanForgivenessPeriod
P168D
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
2537000
CY2020 dei Entity Registrant Name
EntityRegistrantName
International Stem Cell CORP
CY2020 dei Entity File Number
EntityFileNumber
0-51891
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4494098
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001355790
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
5950 Priestly Drive
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92008
CY2020 dei City Area Code
CityAreaCode
760
CY2020 dei Local Phone Number
LocalPhoneNumber
940-6383
CY2020Q2 dei Entity Public Float
EntityPublicFloat
2853000
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7539089
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q4 us-gaap Cash
Cash
689000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
403000
CY2020Q4 us-gaap Inventory Net
InventoryNet
917000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
174000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
2183000
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
371000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
534000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1262000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1483000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1913000
CY2020Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
2475000
CY2019Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
2370000
CY2020 dei Security12g Title
Security12gTitle
Common Stock, $0.001 par value per share
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109115000
CY2020 dei Security Exchange Name
SecurityExchangeName
NONE
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-106391000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-4333000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-2888000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5287000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6620000
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2019Q4 us-gaap Cash
Cash
484000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1515000
CY2019Q4 us-gaap Inventory Net
InventoryNet
1246000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
207000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Assets Current
AssetsCurrent
3452000
CY2019Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
358000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
668000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1335000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
874000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
717000
CY2020Q4 isco Deposits And Other Assets
DepositsAndOtherAssets
63000
CY2019Q4 isco Deposits And Other Assets
DepositsAndOtherAssets
90000
CY2020Q4 us-gaap Assets
Assets
5287000
CY2019Q4 us-gaap Assets
Assets
6620000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
360000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
654000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
386000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
642000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
346000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
367000
CY2020Q4 isco Advances From Nonaffiliated Collaboration
AdvancesFromNonaffiliatedCollaboration
250000
CY2019Q4 isco Advances From Nonaffiliated Collaboration
AdvancesFromNonaffiliatedCollaboration
250000
CY2020Q4 isco Paycheck Protection Program Loan Current
PaycheckProtectionProgramLoanCurrent
141000
CY2020Q4 isco Paycheck Protection Program Loan Noncurrent
PaycheckProtectionProgramLoanNoncurrent
517000
CY2019Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
207000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
845000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
718000
CY2020Q4 us-gaap Liabilities
Liabilities
5320000
CY2019Q4 us-gaap Liabilities
Liabilities
5208000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
104769000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103490000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2087000
CY2020 us-gaap Profit Loss
ProfitLoss
-2724000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1279000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
253000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
285000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7539089
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7539089
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7539089
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7539089
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7128000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9472000
CY2020 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2019 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2019 us-gaap Cost Of Revenue
CostOfRevenue
3933000
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
9946000
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
15200000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-5728000
CY2020 us-gaap Interest Expense
InterestExpense
113000
CY2019 us-gaap Interest Expense
InterestExpense
77000
CY2019 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
94000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1463000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-2724000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-4265000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7539000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7513000
CY2019 isco Adjustments Related To Error Correction In Equity
AdjustmentsRelatedToErrorCorrectionInEquity
-4300000
CY2019 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1049000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4000
CY2019 us-gaap Profit Loss
ProfitLoss
-4265000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
265000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
289000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
1279000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
2087000
CY2019 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
4000
CY2019 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
73000
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
65000
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1540000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1112000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
864000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-316000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-702000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-33000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-336000
CY2020 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-27000
CY2019 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
12000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-294000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
196000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-256000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
74000
CY2020 isco Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-315000
CY2019 isco Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-304000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-341000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1397000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
164000
CY2020 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
80000
CY2019 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
330000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-108000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-494000
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
654000
CY2019 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1300000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
654000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1300000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
205000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-591000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
484000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1075000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
689000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
5000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
5000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
421000
CY2020 isco Patent License Costs Included In Accrued Liabilities
PatentLicenseCostsIncludedInAccruedLiabilities
3000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1187000
CY2020 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2019, the Company reclassified certain prior period amounts to conform to the current period presentation, as follows:</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying value and shares of the Company&#8217;s Series&#160;B, Series&#160;G, Series&#160;I-1 and Series&#160;I-2 non-redeemable convertible preferred stock were aggregated on the accompanying consolidated balance sheets and consolidated statements of changes in redeemable convertible preferred stock and stockholders&#8217; deficit. Refer to Note&#160;6&#160;&#8211;&#160;Convertible Preferred Stock, for further discussion;</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash operating lease expense was reclassified from changes in operating assets and liabilities to adjustments to reconcile net loss to net cash used in operating activities on the accompanying consolidated statements of cash flows; and</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allowance for inventory obsolescence was reclassified from adjustments to reconcile net loss to net cash used in operating expenses to inventory, net, in the changes in operating assets and liabilities on the accompanying consolidated statements of cash flows.</p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These reclassifications had no effect on previously reported net loss, stockholders&#8217; deficit, or cash flows for the prior period.</p>
CY2020Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying consolidated financial statements. Significant estimates include patent life (remaining legal life versus remaining useful life), inventory carrying values, allowance for excess and obsolete inventories, allowance for sales returns and doubtful accounts, and transactions using the Black-Scholes option valuation model, for example, common stock options and warrants, as well as the Monte-Carlo simulation method for certain common stock warrants. Actual results could differ from those estimates.</p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Customer Concentrations</p> <p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31,&#160;2020, one major customer accounted for approximately 41% of product sales. For the year ended December&#160;31,&#160;2019, two major customers accounted for 37% and 15% of product sales, respectively. No other single customer accounted for more than 10% of product sales for the year ended.</p>
CY2020 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1099000
CY2020Q4 isco Indefinite Life Logos And Trademarks
IndefiniteLifeLogosAndTrademarks
75000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1262000
CY2020 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
65000
CY2020Q2 isco Cares Act Of2020 Aid Amount
CARESActOf2020AidAmount
654000
CY2020Q2 isco Paycheck Protection Program Loan Interest Rate
PaycheckProtectionProgramLoanInterestRate
0.01
CY2020Q2 isco Paycheck Protection Program Loan Deferred Payment Period
PaycheckProtectionProgramLoanDeferredPaymentPeriod
P10M
CY2020 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2020 isco Number Of Business Units
NumberOfBusinessUnits
2
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12000
CY2008Q2 isco Advances From Nonaffiliated Collaboration
AdvancesFromNonaffiliatedCollaboration
250000
CY2008Q2 isco Specified Amount Of Revenue To Be Utilized First For Advances
SpecifiedAmountOfRevenueToBeUtilizedFirstForAdvances
250000
CY2020 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P15Y
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
156000
CY2020Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
2286000
CY2019Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
2268000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1008000
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2020Q4 isco Number Of Products Categories
NumberOfProductsCategories
2
CY2020 isco Number Of Sales Channels
NumberOfSalesChannels
2
CY2020 us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
The Company's revenue consists primarily of sales of products from its two revenue-generating operating segments, the biomedical products market and anti-aging products market. The biomedical market segment markets and sells primary human cell research products with two product categories, cells and media, which are sold both domestically within the United States and internationally. The anti-aging market segment markets and sells a line of skincare products sold through two sales channels: ecommerce and professional. The ecommerce channel sells direct to customers through online orders, while professional sales are to spas, salons and other skincare providers
CY2020 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2019 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2020 isco Product Return Guarantee Period
ProductReturnGuaranteePeriod
P30D
CY2020 isco Allowance For Sales Return
AllowanceForSalesReturn
0
CY2019 isco Allowance For Sales Return
AllowanceForSalesReturn
0
CY2020Q4 isco Financial Assets Fair Value Disclosure
FinancialAssetsFairValueDisclosure
0
CY2020Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2018Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1745000
CY2019Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
207000
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14734547
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15020003
CY2020Q4 us-gaap Change In Accounting Principle Accounting Standards Update Adopted
ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
true
CY2020Q4 us-gaap Change In Accounting Principle Accounting Standards Update Adoption Date
ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
2020-01-01
CY2020Q4 us-gaap Change In Accounting Principle Accounting Standards Update Immaterial Effect
ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
true
CY2020 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201813Member
CY2020Q4 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1288000
CY2020 us-gaap Inventory Write Down
InventoryWriteDown
131000
CY2019 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3438000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3410000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2904000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2742000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
162000
CY2019 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
1.5
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1260000
CY2019Q4 isco Indefinite Life Logos And Trademarks
IndefiniteLifeLogosAndTrademarks
75000
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1335000
CY2020Q4 isco Finite Lived Pending Patents
FiniteLivedPendingPatents
139000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
93000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2020 us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
The holders of Series B, Series D, and Series G are entitled to one vote for each share of common stock into which it would convert. The holders of Series I-1 and Series I-2 have no voting rights
CY2019Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1000000
CY2019Q1 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
49000
CY2020 isco Convertible Common Stock Conversion Price
ConvertibleCommonStockConversionPrice
1.75
CY2014Q4 isco Class Of Warrant Or Right Issued Exercisable For Shares Of Common Stock
ClassOfWarrantOrRightIssuedExercisableForSharesOfCommonStock
62047
CY2016Q1 isco Class Of Warrant Or Right Issued Exercisable For Shares Of Common Stock
ClassOfWarrantOrRightIssuedExercisableForSharesOfCommonStock
11159995
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.75
CY2016Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.75
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
19617322
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
604000
CY2019 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M3D
CY2019Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
800000
CY2019Q4 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
500000
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
500000
CY2020 isco Operating Loss Carryforwards Latest Expiration Year
OperatingLossCarryforwardsLatestExpirationYear
2037
CY2020 isco Operating Loss Carryforwards Expiration Date Description
OperatingLossCarryforwardsExpirationDateDescription
various years through 2037
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 isco Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.028
CY2019 isco Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.030
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.004
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.003
CY2019 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.050
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.191
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.131
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Leases
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases
-0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Leases
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases
0.018
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.054
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.183
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.068
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.010
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020 isco Loss Carryback Period
LossCarrybackPeriod
P5Y
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
18452000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1980000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2871000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
547000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
24384000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23850000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
24384000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
23850000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2020 isco Number Of Operating Leases
NumberOfOperatingLeases
3
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1191000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
464000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
490000
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
7000
CY2019 us-gaap Short Term Lease Cost
ShortTermLeaseCost
11000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
211000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
228000
CY2020 us-gaap Lease Cost
LeaseCost
682000
CY2019 us-gaap Lease Cost
LeaseCost
729000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
509000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
486000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y10M24D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y7D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1705
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1765
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
517000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
394000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
255000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
233000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
240000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1639000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
448000

Files In Submission

Name View Source Status
0001564590-21-016653-index-headers.html Edgar Link pending
0001564590-21-016653-index.html Edgar Link pending
0001564590-21-016653.txt Edgar Link pending
0001564590-21-016653-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
grytwfbrv2ap000001.jpg Edgar Link pending
grytwfbrv2ap000002.jpg Edgar Link pending
isco-10k_20201231.htm Edgar Link pending
isco-20201231.xml Edgar Link completed
isco-20201231.xsd Edgar Link pending
isco-20201231_cal.xml Edgar Link unprocessable
isco-20201231_def.xml Edgar Link unprocessable
isco-20201231_lab.xml Edgar Link unprocessable
isco-20201231_pre.xml Edgar Link unprocessable
isco-ex1017_294.htm Edgar Link pending
isco-ex231_8.htm Edgar Link pending
isco-ex311_6.htm Edgar Link pending
isco-ex312_9.htm Edgar Link pending
isco-ex321_11.htm Edgar Link pending
isco-ex322_7.htm Edgar Link pending
isco-ex47_187.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending